Grant: Catalyst Grant: Post Market Drug Safety and Effectiveness
University of British Columbia
$99,255.00
Vincristine-induced Peripheral Neuropathy in Children with Cancer.
EF 2009-10
Résumé
Vincristine is a highly effective drug that is frequently used for the treatment of childhood cancer. However, the use of vincristine is significantly restricted by the incidence of a harmful adverse drug reaction (ADR) that causes disruption of the nerves of the peripheral nervous system in 4-28% of pediatric patients (16.6% in our study). Even at standard doses, this neuropathy may cause severe pain, burning sensations, or complete loss of sensation in hands and feet. In some patients vincristine neuropathy can be fatal, causing severe bowel dysfunction or paralysis of the vocal cords that requires emergency intubation and prolonged mechanical ventilation.
At present, there is no way to know which patients will develop this severe adverse effect. Due to the significant inter-individual variation in responses to vincristine, we hypothesize that genetic differences in enzymes that control how vincristine is metabolized in the body may determine a patient's susceptibility to this severe ADR.
We propose to identify the genetic variants that increase susceptibility to vincristine-induced peripheral neuropathy in children. We have already identified and collected DNA samples from over 100 children with serious vincristine-induced neuropathy, as well as over 500 drug matched control children that have received similar doses of vincristine without developing neuropathy. We will use these DNA samples to identify genetic susceptibility variants for vincristine-peripheral neuropathy by testing the patient DNA samples for 4600 genetic variations in genes that are known to control the metabolism, transport, and excretion of drugs in the body.
Our results will be used to develop a diagnostic test that could identify patients at high risk of this devastating adverse effect. The availability of a diagnostic test to safely select drugs and doses for individual patients will provide a vital, cost-effective, and potentially life-saving tool for clinicians.
Programme
Catalyst Grant: Post Market Drug Safety and Effectiveness
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
192652
Name
Carleton Bruce C
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Catalyst Grant: Post Market Drug Safety and Effectiveness
Projecttitle
Vincristine-induced Peripheral Neuropathy in Children with Cancer.
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$99,255
Cihrequipment2
$0
Programname2
Catalyst Grant: Post Market Drug Safety and Effectiveness
Keyworddelim
Cancer; Children; Peripheral Neuropathy; Pharmacogenomics; Vincristine
Abstract
Vincristine is a highly effective drug that is frequently used for the treatment of childhood cancer. However, the use of vincristine is significantly restricted by the incidence of a harmful adverse drug reaction (ADR) that causes disruption of the nerves of the peripheral nervous system in 4-28% of pediatric patients (16.6% in our study). Even at standard doses, this neuropathy may cause severe pain, burning sensations, or complete loss of sensation in hands and feet. In some patients vincristine neuropathy can be fatal, causing severe bowel dysfunction or paralysis of the vocal cords that requires emergency intubation and prolonged mechanical ventilation.
At present, there is no way to know which patients will develop this severe adverse effect. Due to the significant inter-individual variation in responses to vincristine, we hypothesize that genetic differences in enzymes that control how vincristine is metabolized in the body may determine a patient's susceptibility to this severe ADR.
We propose to identify the genetic variants that increase susceptibility to vincristine-induced peripheral neuropathy in children. We have already identified and collected DNA samples from over 100 children with serious vincristine-induced neuropathy, as well as over 500 drug matched control children that have received similar doses of vincristine without developing neuropathy. We will use these DNA samples to identify genetic susceptibility variants for vincristine-peripheral neuropathy by testing the patient DNA samples for 4600 genetic variations in genes that are known to control the metabolism, transport, and excretion of drugs in the body.
Our results will be used to develop a diagnostic test that could identify patients at high risk of this devastating adverse effect. The availability of a diagnostic test to safely select drugs and doses for individual patients will provide a vital, cost-effective, and potentially life-saving tool for clinicians.
Competitiondate
200910
Approvedterm2
1 yr 0 mth
Pinamesdelim
Carleton, Bruce C; Hayden, Michael R
Approvedterm
1 an 0 mois
Cihrcontribution2
Inst of Cancer Research~ $6,465~ $0~~ $92,790~ $0~